Derm-Biome Pharmaceuticals Inc. has reported findings from a study of its topical drug DB-007-5 in a well-established preclinical model of human atopic dermatitis.
Derm-Biome Pharmaceuticals Inc. has developed a topical anticancer treatment for patients with or at high risk of developing multiple actinic keratoses. In a recent UV-induced skin cancer study, mice ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback